Be the first person to write a business review for MAP Pharmaceuticals, Inc.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.

NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its proprietary Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial and viral infections. NovaBay company's lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also offers NVC-101, a proprietary solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions, as well as an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo, and other dermatological indications. NovaBay company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in August 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.